AMNOG assessment report misses key factors for industry
This article was originally published in Scrip
Executive Summary
A government report on Germany's tough AMNOG pricing and reimbursement system has failed to address key problems with the system, according to Matthias Heck, Brussels representative for the BPI, a German pharmaceutical industry association.